Purpose and Summary
The Honor Our Living Donors Act prevents an organ recipient's income from being considered when providing reimbursement for qualifying expenses incurred by a living organ donor during the donation process.
house · Committee report
HONOR OUR LIVING DONORS ACT
2024-07-23
The Honor Our Living Donors Act prevents an organ recipient's income from being considered when providing reimbursement for qualifying expenses incurred by a living organ donor during the donation process.
The Organ Donation and Recovery Improvement Act (ODRIA) established the authority and parameters to provide reimbursement to living organ donors for lost wages, dependent care, travel, and incidental expenses during the donation process.\1\ Since this law was established, the Health Resources and Services Administration (HRSA) began supporting the National Living Donor Assistance Center (NLDAC) to implement the reimbursement program and this has helped make more than 9,000 organ donations possible.\2\ While this program has clearly helped living donors, it is important to reduce barriers to organ donation as there are more than 103,000 patients on the national transplant waiting list.\3\ --------------------------------------------------------------------------- \1\Public Law 108-216, Organ Donation and Recovery Improvement Act, Section 3. \2\National Living Donor Assistance Center, Our Mission, https:// www.livingdonorassistance.org/. \3\Health Resources and Services Administration, Organ Donation Statistics, https://www.organdonor.gov/learn/organ-donation-statistics. --------------------------------------------------------------------------- Under current law, the living donor's reimbursement eligibility status is based on the income of both the donor and recipient.\4\ This has proven to be an unnecessary barrier to living organ donation and has resulted in most living organ donors financing their own donations. H.R. 6020 removes the requirement for eligibility status to be determined based on the income of the intended recipient with the ultimate goal of increasing organ donation rates. --------------------------------------------------------------------------- \4\Public Health Service Act, Section 377. ---------------------------------------------------------------------------
On February 29, 2024, the Subcommittee on Health held a hearing on H.R. 6020. The title of the hearing was ``Legislative Proposals to Support Patients with Rare Diseases.'' The Subcommittee received testimony from: Terence Flotte, MD, Provost and Dean of UMass Chan Medical School, Vice President of American Society of Gene and Cell Therapy; Alexander Bassuk, MD, PhD, Physician-in- Chief, University of Iowa Stead Family Children's Hospital; Chair and Professor, Stead Family Department of Pediatrics; Aaron Kesselheim, MD, JD, MPH, Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital; Jeromie Ballreich, PhD, Associate Research Professor, Johns Hopkins Bloomberg School of Public Health; Alice Chen, PhD, Senior Fellow, USC Schaeffer Center for Health Policy and Economics; Associate Professor and Vice Dean for Research, USC Sol Price School of Public Policy; and Khrystal Davis, JD, Founding President, Texas Rare Alliance. On May 16, 2024, the Subcommittee on Health met in open markup session and forwarded H.R. 6020, as amended, to the full Committee by a roll call vote of 24 yeas to 0 nays. On June 12, 2024, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 6020, as amended, favorably reported to the House by a record vote of 42 yeas and 0 nays.
Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 6020 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.
Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to eliminate consideration of the income of organ recipients in providing reimbursement of expenses to donating individuals. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 6020 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 6020: On February 29, 2024, the Subcommittee on Health held a hearing on H.R. 6020. The title of the hearing was ``Legislative Proposals to Support Patients with Rare Diseases.'' The Subcommittee received testimony from: Terence Flotte, MD, Provost and Dean of UMass Chan Medical School, Vice President of American Society of Gene and Cell Therapy; Alexander Bassuk, MD, PhD, Physician-in-Chief, University of Iowa Stead Family Children's Hospital; Chair and Professor, Stead Family Department of Pediatrics; Aaron Kesselheim, MD, JD, MPH, Professor of Medicine, Harvard Medical School; Director, Program On Regulation, Therapeutics, And Law (PORTAL) at Brigham and Women's Hospital; Jeromie Ballreich, PhD, Associate Research Professor, Johns Hopkins Bloomberg School of Public Health; Alice Chen, PhD, Senior Fellow, USC Schaeffer Center for Health Policy and Economics; Associate Professor and Vice Dean for Research, USC Sol Price School of Public Policy; and Khrystal Davis, JD, Founding President, Texas Rare Alliance. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 6020 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides that the Act may be cited as the ``Honor Our Living Donors Act.'' Section 2. No consideration of income of organ recipient Section 2 provides that there shall be no consideration of income of the organ recipient when determining reimbursement eligibility for the living organ donor. Section 3. Removal of expectation of payments of organ recipients Section 3 provides that there shall be no consideration of whether the organ recipient could reasonably make payments to the living donor for qualified expenses. Section 4. Annual report Section 4 requires the Secretary of the Department of Health and Human Services to prepare and submit a report to Congress on whether grants under this section provided adequate funding to reimburse all donating individuals for qualifying expenses. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): PUBLIC HEALTH SERVICE ACT * * * * * * * TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE * * * * * * * Part H--Organ Transplants * * * * * * * SEC. 377. REIMBURSEMENT OF TRAVEL AND SUBSISTENCE EXPENSES INCURRED TOWARD LIVING ORGAN DONATION. (a) In General.--The Secretary may award grants to States, transplant centers, qualified organ procurement organizations under section 371, or other public or private entities for the purpose of-- (1) providing for the reimbursement of travel and subsistence expenses incurred by individuals toward making living donations of their organs (in this section referred to as ``donating individuals''); and (2) providing for the reimbursement of such incidental nonmedical expenses that are so incurred as the Secretary determines by regulation to be appropriate. (b) Preference.--The Secretary shall, in carrying out subsection (a), give preference to those individuals that the Secretary determines are more likely to be otherwise unable to meet such expenses. (c) No Consideration of Income of Organ Recipient.--The recipient of a grant under this section, in providing reimbursement to a donating individual through such grant, shall not give any consideration to the income of the organ recipient. [(c)] (d) Certain Circumstances.--The Secretary may, in carrying out subsection (a), consider-- (1) the term ``donating individuals'' as including individuals who in good faith incur qualifying expenses toward the intended donation of an organ but with respect to whom, for such reasons as the Secretary determines to be appropriate, no donation of the organ occurs; and (2) the term ``qualifying expenses'' as including the expenses of having relatives or other individuals, not to exceed 2, accompany or assist the donating individual for purposes of subsection (a) (subject to making payment for only those types of expenses that are paid for a donating individual). [(d)] (e) Relationship to Payments Under Other Programs.--An award may be made under subsection (a) only if the applicant involved agrees that the award will not be expended to pay the qualifying expenses of a donating individual to the extent that payment has been made, or can reasonably be expected to be made, with respect to such expenses-- (1) under any State compensation program, under an insurance policy, or under any Federal or State health benefits program; or (2) by an entity that provides health services on a prepaid basis[; or]. [(3) by the recipient of the organ.] [(e)] (f) Definitions.--For purposes of this section: (1) The term ``donating individuals'' has the meaning indicated for such term in subsection (a)(1), subject to [subsection (c)(1)] subsection (d)(1). (2) The term ``qualifying expenses'' means the expenses authorized for purposes of subsection (a), subject to [subsection (c)(2)] subsection (d)(2). [(f)] (g) Authorization of Appropriations.--For the purpose of carrying out this section, there is authorized to be appropriated $5,000,000 for each of the fiscal years 2005 through 2009. (h) Annual Report.--Not later than December 31 of each year, the Secretary shall-- (1) prepare, submit to the Congress, and make public a report on whether grants under this section provided adequate funding during the preceding fiscal year to reimburse all donating individuals participating in the grant program under this section for all qualifying expenses; and (2) include in each such report-- (A) the estimated number of all donating individuals participating in the grant program under this section who did not receive reimbursement for all qualifying expenses during the preceding fiscal year; and (B) the total amount of funding that is estimated to be necessary to fully reimburse all donating individuals participating in the grant program under this section for all qualifying expenses. * * * * * * * [all]
Source: https://api.congress.gov/v3/committee-report/118/hrpt/611